US2009220524A1PendingUtilityA1

Therapeutic agents for alzheimer's disease and cancer

55
Assignee: UNIV TOKYOPriority: Apr 25, 2006Filed: Apr 23, 2007Published: Sep 3, 2009
Est. expiryApr 25, 2026(expired)· nominal 20-yr term from priority
Inventors:Takeshi IwatsuboTatsuhiko KodamaTakao HamakuobTaisuke TomitaIkuo HayashiYasuomi UranoHiroko IwanariMasao Ohkuchi
A61P 35/00A61P 43/00A61P 35/02A61K 2039/505A61P 25/28C07K 2317/73G01N 2500/02C07K 16/40C07K 2317/76G01N 2333/948G01N 33/6896G01N 33/575
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.

Claims

exact text as granted — not AI-modified
1 . A therapeutic drug for Alzheimer's disease and/or a cancer containing an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative. 
     
     
         2 . The therapeutic drug as described in  claim 1 , wherein the cancer is a nicastrin-expressing cancer. 
     
     
         3 . The therapeutic drug for a cancer as described in  claim 1 , wherein the cancer is a γ-secretase-dependent cancer. 
     
     
         4 . The therapeutic drug as described in  claim 1 , wherein the cancer is lung cancer or T-cell acute lymphoblastic leukemia. 
     
     
         5 . A screening method for selecting an antibody which inhibits γ-secretase activity, characterized by comprising reacting nicastrin with a γ-secretase substrate in the presence of a test antibody. 
     
     
         6 . Use of an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative for producing a therapeutic drug for Alzheimer's disease and/or a cancer. 
     
     
         7 . Use as described in  claim 6 , wherein the cancer is a nicastrin-expressing cancer. 
     
     
         8 . Use as described in  claim 6 , wherein the cancer is a γ-secretase-dependent cancer. 
     
     
         9 . Use as described in  claim 6 , wherein the cancer is lung cancer or T-cell acute lymphoblastic leukemia. 
     
     
         10 . A method for treatment of Alzheimer's disease and/or a cancer, comprising administering an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative to a subject in need thereof. 
     
     
         11 . The method as described in  claim 10 , wherein the cancer is a nicastrin-expressing cancer. 
     
     
         12 . The method as described in  claim 10 , wherein the cancer is a γ-secretase-dependent cancer. 
     
     
         13 . The method as described in  claim 10 , wherein the cancer is lung cancer or T-cell acute lymphoblastic leukemia.

Join the waitlist — get patent alerts

Track US2009220524A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.